title: Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects.
abstract: Recombinant human erythropoietin (EPO) therapy in uremic patients raises the hematocrit (Hct) and increases physical exercise capacity (1,2) and quality of life (1). In general, partial correction of anemia to subnormal levels in uremic patients has proven to be safe with few serious adverse effects apart from hypertension (3). Ever since the advent of EPO the prospect of abuse of the hormone by sportsmen has been subject to scrutiny. Both maximal oxygen uptake and endurance capacity are increased after EPO treatment in healthy subjects (4). Moreover, EPO treatment in healthy subjects has been found to induce an accentuated blood pressure reaction after submaximal exercise (5). Previous studies have shown that extreme physical exertion can predispose to an increased intravascular coagulation (6). Moreover there is a significantly increased risk of thrombosis in patients with myeloproliferative disorders, particularly in polycythemia vera (7). An enhanced risk of cardiovascular events may therefore arise should sportsmen abuse EPO as a blood doping agent. The aim of this study was to examine the effects of an EPO-induced increase in Hct on the coagulation system in healthy subjects.
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000032:analysis*; D001780:Blood Coagulation Tests; D004921:Erythropoietin / Q000009:adverse effects / Q000494:pharmacology*; D005344:Fibrinopeptide A / Q000032:analysis; D006400:Hematocrit; D006801:Humans; D008297:Male; D010447:Peptide Hydrolases / Q000032:analysis*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology; D012016:Reference Values; D012306:Risk; D013178:Sports Medicine; D019966:Substance-Related Disorders; D013923:Thromboembolism / Q000139:chemically induced
chemical_list: D011994:Recombinant Proteins; C046193:antithrombin III-protease complex; D004921:Erythropoietin; D005344:Fibrinopeptide A; D000990:Antithrombin III; D010447:Peptide Hydrolases